Pathogenic myeloid phenotypes drive disease pathology in a novel human neurohistiocytosis model

S Shivakumar Rajamanickam (1Department of Pediatrics, University of California San Diego, La Jolla, CA) S Samantha Trescott (1Department of Pediatrics, University of California San Diego, La Jolla, CA) S Samantha Mak (1Department of Pediatrics, University of California San Diego, La Jolla, CA) A Anna S. Warden (Center for Alcohol and Addiction Research, The University of Texas at Austin) A Amanda M. Wilpitz (1Department of Pediatrics, University of California San Diego, La Jolla, CA) B Bing Xia C Celina Nguyen (1Department of Pediatrics, University of California San Diego, La Jolla, CA) H Hilda Ding (1Department of Pediatrics, University of California San Diego, La Jolla, CA) J Jennifer Picarsic (3Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA) C Christopher K. Glass (Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, CA, USA.) C Carl E. Allen (6Texas Children’s Cancer and Hematology Center, Texas Children’s Hospital, Houston, TX) N Nicole G. Coufal

Abstract

Abstract Innate immunity is increasingly recognized as a driver of neurodegeneration, although pathogenic mechanisms are incompletely understood. Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplastic disorder caused by activating somatic mutations in MAPK pathway genes, most commonly BRAFV600E, in myeloid precursors. A subset of patients with LCH develop progressive neurodegeneration (LCH-ND). We generated a human induced pluripotent stem cell (iPSC) model from patients with somatic hematologic mosaicism for BRAFV600E. Brain macrophages/microglia from LCH iPSCs exhibit unique disease-specific pathogenic features. Stepwise differentiation identified hematopoietic progenitors as hyperproliferative, whereas brain macrophages were apoptosis resistant. Through application of cerebral organoids and a humanized murine xenotransplantation model, we identify marked heterogeneity of differentiation potential within clonal BRAFV600E lines in vivo. This model phenocopied human-specific phenotypes, including dense basal ganglia foci of abnormal macrophages, marked neurodegeneration with astrogliosis, and progressive ataxia. This approach will allow for preclinical testing of therapeutics for LCH-ND.

Article Details

Journal Blood
Volume / Issue Vol. 148, Issue 4
Published July 23, 2026
Pages 433-449
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (12)

S

Shivakumar Rajamanickam

1Department of Pediatrics, University of California San Diego, La Jolla, CA

S

Samantha Trescott

1Department of Pediatrics, University of California San Diego, La Jolla, CA

S

Samantha Mak

1Department of Pediatrics, University of California San Diego, La Jolla, CA

A

Anna S. Warden

Center for Alcohol and Addiction Research, The University of Texas at Austin

A

Amanda M. Wilpitz

1Department of Pediatrics, University of California San Diego, La Jolla, CA

B

Bing Xia

C

Celina Nguyen

1Department of Pediatrics, University of California San Diego, La Jolla, CA

H

Hilda Ding

1Department of Pediatrics, University of California San Diego, La Jolla, CA

J

Jennifer Picarsic

3Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA

C

Christopher K. Glass

Department of Cellular and Molecular Medicine, University of California, San Diego School of Medicine, La Jolla, CA, USA.

C

Carl E. Allen

6Texas Children’s Cancer and Hematology Center, Texas Children’s Hospital, Houston, TX

N

Nicole G. Coufal